barzolvolimab   Click here for help

GtoPdb Ligand ID: 11607

Synonyms: CDX-0159
Compound class: Antibody
Comment: Barzolvolimab (CDX-0159) is a clinical stage humanized anti-KIT IgG1 monoclonal antibody that was developed by Celldex Therapeutics (as claimed in their patent US10781267B2) [1]. CDX-0159 is a variant of CDX-0158 (a.k.a. KTN0158 [2]) that was re-engineered to improve its safety profile and increase its serum half-life. CDX-0158 was originally designed for potential to treat GIST and other KIT-dependent tumours. This original version of the antibody inhibits mutant and wild type KIT phosphorylation, reduces mast cell degranulation and mast cell numbers, and shrinks tumours in a preclinical canine model of spontaneous mast cell tumour development [2].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11842 barzolvolimab
Synonyms Click here for help
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1205
Other databases
GtoPdb PubChem SID 442878641
Search PubMed clinical trials barzolvolimab
Search PubMed titles barzolvolimab
Search PubMed titles/abstracts barzolvolimab